




PHARMACEUTICAL 2017

Allergan plc
Rank 90 of 292





PHARMACEUTICAL 2017

Allergan plc
Rank 90 of 292

The relative strengths and weaknesses of Allergan plc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Allergan plc compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 220% points. The greatest weakness of Allergan plc is the variable Other Liabilities, reducing the Economic Capital Ratio by 115% points.

The company's Economic Capital Ratio, given in the ranking table, is 160%, being 157% points above the market average of 2.9%.

Input Variable	Value in 1000 USD
Assets, Current	17,857,900
Cost of Goods Sold	0
Intangible Assets	108,974,700
Liabilities, Current	7,874,700
Liabilities, Non-Current	1,085,000
Other Assets	542,400
Other Compr. Net Income	-550,400
Other Expenses	10,449,500
Other Liabilities	43,826,100
Other Net Income	14,908,000
Other Revenues	14,570,600
Property and Equipment	1,611,300
Research and Development	2,575,700
Selling, General and Administrative Expense	1,473,900

Output Variable	Value in 1000 USD
Assets	128,986,300
Liabilities	52,785,800
Expenses	14,499,100
Revenues	14,570,600
Stockholders Equity	76,200,500
Net Income	14,979,500
Comprehensive Net Income	14,704,300
Economic Capital Ratio	160%